News | Atrial Fibrillation | October 25, 2016

New Study Compares Stroke Prevention Treatments for Non-valvular Atrial Fibrillation Patients

Results suggest no one treatment is universally appropriate, and treatment must be personalized to patients

UAB, University of Alabama at Birmingham study, stroke prevention, non-valvular atrial fibrillation, NVAF

October 25, 2016 — A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE compares different available treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF).

The group identified six clinical trials with 59,627 patients comparing six different U.S. Food and Drug Administration (FDA)-approved treatment alternatives. The study combined all phase-three randomized controlled clinical trials comparing different novel oral blood thinners, left atrial appendage closure (Watchman) devices and Coumadin (warfarin) for stroke prevention in patients with NVAF. Investigators reported data on ischemic stroke, major bleeding and primary safety endpoint from these clinical trials.

Watchman left atrial appendage devices are used as an alternative to long-term warfarin therapy for stroke risk-reduction patients with non-valvular atrial fibrillation.

UAB doctors say too many options may not be a good thing.

“The occurrence of multiple treatment pathways has presented dilemmas for the clinicians,” said Navkaranbir S. Bajaj, M.D., the first author of the PLOS ONE study who designed and conducted the analyses for the study.

“We exploited the fact that no direct comparisons from trials were available between Watchman and novel oral anticoagulants,” said Bajaj, instructor fellow in the division of cardiovascular disease.

The study explains that, while direct evidence from randomized controlled trials is lacking, indirect comparisons using systematic network meta-analyses can provide useful complementary information that may be less biased than the direct evidence.

Researchers have found that all treatments had comparable efficacy in reducing stroke rates. However, Apixaban, one of the novel oral blood thinners, was a clear winner in terms of safety profile, and the Watchman device was ranked last due to a higher number of procedural adverse events.

“In an era of precision medicine, we need to individualize treatment for our patients,” said senior author Pankaj Arora, M.D., assistant professor in the Division of Cardiovascular Disease. “Our current analysis gives insight into how one can do that to prevent stroke in patients with atrial fibrillation.”

Arora said one size does not fit all, and his clinical translational research group is actively working to apply this order to all cardiovascular diseases. The authors concluded that the trade-off between safety and efficacy should be the driving force, and the hierarchical ranking presented in this paper can serve as a clinical tool to guide selection of therapy in patients with atrial fibrillation.

For more information: www.plosone.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init